WAVE LIFE SCIENCES LTD. (WVE) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
36/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseWVE / S&P -19.86% / 15.20% |
LoseWVE / S&P WVE unavailable / 15.00% |
LoseWVE / S&P 35.00% / 50.40% |
| 2026-Q11/3 |
LoseWVE / S&P -57.35% / -4.33% |
LoseWVE / S&P WVE unavailable / 11.30% |
WinWVE / S&P 41.89% / 27.70% |
| 2025-Q42/3 |
WinWVE / S&P 132.24% / 2.65% |
LoseWVE / S&P WVE unavailable / 9.00% |
WinWVE / S&P 75.36% / 13.40% |
| 2025-Q31/3 |
WinWVE / S&P 12.62% / 8.12% |
LoseWVE / S&P WVE unavailable / 4.61% |
LoseWVE / S&P -41.44% / 13.45% |
| 2025-Q21/3 |
LoseWVE / S&P -19.55% / 10.94% |
LoseWVE / S&P WVE unavailable / 4.83% |
WinWVE / S&P 40.35% / 10.63% |
| 2025-Q11/3 |
LoseWVE / S&P -34.68% / -4.27% |
LoseWVE / S&P WVE unavailable / 4.98% |
WinWVE / S&P 42.31% / 10.57% |
| 2024-Q42/3 |
WinWVE / S&P 50.85% / 2.41% |
LoseWVE / S&P WVE unavailable / 5.25% |
WinWVE / S&P 25.45% / 6.15% |
| 2024-Q32/3 |
WinWVE / S&P 64.33% / 5.89% |
LoseWVE / S&P WVE unavailable / 5.89% |
WinWVE / S&P 30.59% / 6.11% |
| 2024-Q21/3 |
LoseWVE / S&P -19.12% / 4.28% |
WinWVE / S&P 202.25% / 5.38% |
LoseWVE / S&P -57.46% / 5.12% |
| 2024-Q12/3 |
WinWVE / S&P 22.18% / 10.56% |
WinWVE / S&P 661.49% / 5.71% |
LoseWVE / S&P -70.45% / 5.59% |
| 2023-Q41/3 |
LoseWVE / S&P -12.17% / 11.69% |
WinWVE / S&P 3005.10% / 6.81% |
LoseWVE / S&P -73.93% / 7.78% |
| 2023-Q32/3 |
WinWVE / S&P 57.97% / -3.27% |
WinWVE / S&P 1947.62% / 7.52% |
LoseWVE / S&P -62.56% / -5.03% |
| 2023-Q20/3 |
LoseWVE / S&P -15.94% / 8.74% |
LoseWVE / S&P -9.31% / 9.50% |
LoseWVE / S&P -31.98% / -8.57% |
| 2023-Q10/3 |
LoseWVE / S&P -38.14% / 7.50% |
LoseWVE / S&P -65.29% / 10.77% |
LoseWVE / S&P -17.37% / -15.69% |
| 2022-Q41/3 |
WinWVE / S&P 93.91% / 7.56% |
LoseWVE / S&P WVE unavailable / 11.88% |
LoseWVE / S&P WVE unavailable / -17.99% |
| 2022-Q31/3 |
WinWVE / S&P 11.08% / -4.88% |
LoseWVE / S&P WVE unavailable / 13.47% |
LoseWVE / S&P WVE unavailable / -1.41% |
| 2022-Q21/3 |
WinWVE / S&P 62.50% / -16.10% |
LoseWVE / S&P WVE unavailable / 13.71% |
LoseWVE / S&P WVE unavailable / 11.04% |
| 2022-Q10/3 |
LoseWVE / S&P -36.31% / -4.60% |
LoseWVE / S&P WVE unavailable / 15.97% |
LoseWVE / S&P WVE unavailable / 42.23% |
| 2021-Q40/3 |
LoseWVE / S&P -35.92% / 11.03% |
LoseWVE / S&P WVE unavailable / 15.00% |
LoseWVE / S&P WVE unavailable / 96.40% |
| 2021-Q30/3 |
LoseWVE / S&P -26.43% / 0.58% |
LoseWVE / S&P WVE unavailable / 10.77% |
LoseWVE / S&P WVE unavailable / 69.42% |
| 2021-Q21/3 |
WinWVE / S&P 18.72% / 8.55% |
LoseWVE / S&P WVE unavailable / 6.58% |
LoseWVE / S&P WVE unavailable / 51.81% |
| 2021-Q10/3 |
LoseWVE / S&P -28.72% / 6.17% |
LoseWVE / S&P WVE unavailable / -1.06% |
LoseWVE / S&P WVE unavailable / 7.39% |
| 2020-Q41/3 |
LoseWVE / S&P -7.30% / 12.15% |
WinWVE / S&P 25.61% / -3.72% |
LoseWVE / S&P WVE unavailable / -33.42% |
| 2020-Q30/3 |
LoseWVE / S&P -18.44% / 8.93% |
LoseWVE / S&P -24.21% / -2.04% |
LoseWVE / S&P WVE unavailable / -27.10% |
| 2020-Q20/3 |
LoseWVE / S&P 11.10% / 20.54% |
LoseWVE / S&P -33.30% / -0.46% |
LoseWVE / S&P WVE unavailable / -27.11% |
| 2020-Q12/3 |
WinWVE / S&P 16.83% / -19.60% |
WinWVE / S&P 6.87% / 3.47% |
LoseWVE / S&P WVE unavailable / -14.75% |
| 2019-Q41/3 |
LoseWVE / S&P -60.94% / 9.07% |
WinWVE / S&P 10.89% / 5.36% |
LoseWVE / S&P WVE unavailable / 2.99% |
| 2019-Q31/3 |
LoseWVE / S&P -21.31% / 1.70% |
WinWVE / S&P 44.66% / 5.02% |
LoseWVE / S&P WVE unavailable / 0.21% |
| 2019-Q21/3 |
LoseWVE / S&P -32.84% / 4.30% |
WinWVE / S&P 115.37% / 6.64% |
LoseWVE / S&P WVE unavailable / 8.65% |
| 2019-Q11/3 |
LoseWVE / S&P -7.59% / 13.65% |
WinWVE / S&P 224.78% / 8.12% |
LoseWVE / S&P WVE unavailable / 14.29% |
| 2018-Q41/3 |
LoseWVE / S&P -15.92% / -13.52% |
WinWVE / S&P 270.25% / 9.05% |
LoseWVE / S&P WVE unavailable / 18.23% |
| 2018-Q32/3 |
WinWVE / S&P 30.72% / 7.71% |
WinWVE / S&P 286.35% / 10.21% |
LoseWVE / S&P WVE unavailable / 19.06% |
| 2018-Q21/3 |
LoseWVE / S&P -4.61% / 3.43% |
WinWVE / S&P 304.36% / 9.03% |
LoseWVE / S&P WVE unavailable / 14.46% |
| 2018-Q12/3 |
WinWVE / S&P 14.25% / -0.76% |
WinWVE / S&P 234.37% / 7.68% |
LoseWVE / S&P WVE unavailable / 12.46% |
| 2017-Q41/3 |
WinWVE / S&P 61.38% / 6.64% |
LoseWVE / S&P WVE unavailable / 7.03% |
LoseWVE / S&P WVE unavailable / 13.82% |
| 2017-Q31/3 |
WinWVE / S&P 16.94% / 4.48% |
LoseWVE / S&P WVE unavailable / 5.68% |
LoseWVE / S&P WVE unavailable / 17.57% |
| 2017-Q20/3 |
LoseWVE / S&P -32.36% / 3.09% |
LoseWVE / S&P WVE unavailable / 4.83% |
LoseWVE / S&P WVE unavailable / 17.74% |
| 2017-Q10/3 |
LoseWVE / S&P 5.16% / 6.07% |
LoseWVE / S&P WVE unavailable / 3.67% |
LoseWVE / S&P WVE unavailable / 13.32% |
| 2016-Q40/3 |
LoseWVE / S&P -19.46% / 3.82% |
LoseWVE / S&P WVE unavailable / 2.09% |
LoseWVE / S&P WVE unavailable / 7.05% |
| 2016-Q31/3 |
WinWVE / S&P 56.94% / 3.85% |
LoseWVE / S&P WVE unavailable / 0.20% |
LoseWVE / S&P WVE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | WVE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -46.25% | 20.78% |
| Annualized return | -46.25% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | WVE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -20.62% | 83.14% |
| Annualized return | -4.51% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | WVE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -77.84% | 319.30% |
| Annualized return | -13.99% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |